1. From a screened cohort of 644 67-year-old men, drawn from the population of Gothenburg, 42 men with presumed cardiac dyspnoea were selected and compared with 45 random controls.
INTRODUCTION
a-Human atrial natriuretic peptide (ANP) is a putative hormone released from cardiac atrial myocytes [l] . This peptide has been suggested to be involved in the physiological regulation of water and electrolyte homoeostasis as well as of vascular tone [2] . Raised atrial pressure or stretch is likely to be an important stimulus for ANP release [3- 81, resulting in a rapid response [9] , although other factors may be involved as well [lo] . Increased concentrations of circulating immunoreactive atrial natriuretic peptide (IrANP) have been found in several conditions, particularly in cardiovascular disease, congestive heart failure [ll-171, valvular heart disease [18, 191 , acute myocardial infarction [8] , paroxysmal atrial tachycardia [20] and arterial hypertension [21] , but not in mild essential hypertension [22] . Only slightly elevated IrANP is found in coronary artery disease patients before coronary bypass surgery, while IrANP was increased immediately after discontinuing bypass [23] . The plasma concentration of IrANP is age related [22] , it increases acutely during exercise [7, 24, 25] , and it does not seem to reset in patients with chronic cardiac disease [25] .
Like noradrenaline [26, 271, plasma IrANP might be a potential indicator of morbidity and mortality from cardiac failure [28, 291 , and several clinical studies indicate fairly good correlations between central levels of IrANP and invasive indices of cardiac function in heart failure patients [8, 18, 19, 24, 25, . In order to establish IrANP as a biochemical index of heart failure, it is important to study the plasma concentrations of IrANP not only in selected groups of patients, but also in the population. To our knowledge, there are no epidemiological studies of IrANP. We therefore investigated the venous concentrations of IrANP and catecholamines in randomly selected 67-year-old men from a screened cohort of the general population of Gothenburg, Sweden. Circulating IrANP and catecholamines were evaluated in relation to clinical and non-invasive findings associated with congestive heart failure.
SUBJECTS AND METHODS

Study population
The study population has been described in detail previously . Of all the 817 men born in 1913 on a day divisible by 3 (day 3, day 6, etc. of each month) and living in the city of Gothenburg in 1980 (population 430000), 644 men (79%) agreed to participate in a screening procedure undertaken to evaluate various aspects of dyspnoea in the population.
Dyspnoea was measured using the World Health Organization's modification [37] of the questionnaire proposed by the British Medical Research Council's Committee on the Aetiology of Chronic Bronchitis. Accordingly, we classified dyspnoea into five degrees. Of 644 men participating in the screening procedure, 142 (22%) reported dyspnoea grade 1-4.
The aim of the study was to investigate men with cardiac dyspnoea only. Therefore we selected (by means of clinical investigations, interviews, questionnaires and information from the local Myocardial Infarction Register) those dyspnoeic men who had (1) either angina pectoris, other heart disease, leg oedema at the end of the day, dyspnoea at night, pulmonary rales and/or arterial fibrillation, and (2) no history of chronic bronchitis, asthma or cough, phlegm and wheeze, or rhonchi at the examination. The criteria (1) and (2) were fulfilled by 49 of the 142 men (35%). This study population was investigated by two-dimensional echocardiography [34] and other noninvasive methods [35, 361. An acceptable study by echocardiography was a requirement for inclusion. Of the 49 men, four died from ischaemic heart disease before an echocardiographic investigation could be performed and two declined to participate. One echocardiographic investigation was not interpretable, leaving a study sample of 42 men. In the four dyspnoea grade groups, digtalk/ diuretics/P-blockers were given to 91118 (of 20) men in dyspnoea grade 1, to 4/1/6 (of 12) men in dyspnoea grade 2, to 3/0/2 (of 5) in dyspnoea grade 3, and to 31210 (of 5) in dyspnoea grade 4.
Fifty-one non-dyspnoeic men from the screened population born on day 6 of each month constituted a control group. Of these 51 men, one died from a non-cardiac cause before echocardiography was obtained, four declined to participate, and one investigation was not interpretable. Six of these 45 men in the control group were on /?-blockers (mainly due to hypertension) and three were on digitalis, while no man in the control group received diuretics.
Subjects gave their informed consent to participation in the study, which was approved by the Gothenburg University Research Ethical Committee.
Cardiopulmonary measurements
Dyspnoeic men and control subjects were investigated in random order, and all information was coded with no knowledge of any other data. Pulmonary function was measured as vital capacity. Relative heart volume (ml/m12 body surface area) was calculated from a chest X-ray examination, and venous congestion was estimated visually. Systolic and diastolic blood pressures and heart rate were measured after approximately 45 min of supine rest, using a phonographic method [35] . Q-waves were evaluated from a 12-lead electrocardiogram recorded at a speed of 50 mm/s, and coded according to the Minnesota code [37] . An upright bicycle exercise test was performed with the load increased by 10 W each minute.
Two-dimensional echocardiographic left ventricular wall motion (four standard views) was graded, from hyperkinesia (grade 1) to dyskinesia (grade 7), within 11 anatomical segments as previously described [34] . From M-mode tracings, measurements of the left atrium, left ventricular dimensions and wall thicknesses were obtained in accordance with the recommendations given by the American Society of Echocardiography, end-diastole being defined as the start of the Q-wave. Left ventricular ejection fraction was calculated using the cube formula. Other non-invasive recordings and calculations were performed as previously described 135,361.
In no dyspnoeic or control subject did echocardiographic findings or phonocardiography indicate haemodynamically important organic valvular lesions. Two men (dyspnoea grade 2), who had anterior left ventricular aneurysms, were excluded from measurement of left ventricular dimensions.
IrANP and catecholamines
Blood for IrANP and catecholamine determinations was obtained from an antecubital vein at rest in a sitting posture in the morning (08.00-10.00 hours) after a fasting and non-smoking period of 8-12 h. IrANP was measured using a specific radioimmunoassay technique, as previously described [20] . The assay sensitivity (internal concentration, ICso) was approximately 20-25 pmol/l or 25 pg per tube. The lower detection level was approximately 5 pmol/l. The inter-assay and intra-assay coefficients of variation were 10 and 4%, respectively, in the concentration range measured. Noradrenaline and adrenaline levels in plasma were measured from the same samples as IrANP, using h.p.1.c. with electrochemical detection as described previously [38] . In our laboratory the detection limit for noradrenaline and adrenaline in plasma is 0.1 nmol/l. The inter-assay and intra-assay coefficients of variation are 2 and 4% in the 1-2 nmol/l concentration range.
Statistics
Possible relationships were tested with Pitman's nonparametric permutation test [39] , which, for two groups, is equivalent to Fisher's exact test. For multivariate analyses we used stepwise linear regression technique. P values less than 0.05 were regarded as statistically significant.
RESULTS
The relationships between clinical variables and findings associated with cardiac function on one side, and dyspnoea grade, circulating IrANP, noradrenaline and adrenaline on the other, are summarized in Table 1 . IrANP and noradrenaline, but not adrenaline, correlated significantly (P<O.O5) with dyspnoea grade, but the correlations were low (r=0.26 and r-0.28). Two men reporting dyspnoea grade 2 had increased values of immunoreactivity (Fig. la) . One of these men had a large left ventricle (diastolic dimension 80 mm) and a high amplitude third heart sound, while the other had a possible myocardial infarction and slightly increased atria on two-dimensional echocardiography. On the other hand, two men in dyspnoea grade 2 with antero-apical aneurysms had normal values of IrANP. Noradrenaline was related to vital capacity and to radiological signs of congestion. IrANP was related to radiological heart size and signs of pulmonary congestion. Neither the IrANP concentration nor plasma noradrenaline and adrenaline exhibited strong relationships with indices of ischaemic heart disease, in spite of the correlation between dyspnoea grade and signs and clinical expressions of coronary disease.
Although dyspnoea grade (r= -0.50, P<O.OOl) and ejection fraction ( r = 0.43, P<O.OOl), were related to exercise capacity, IrANP was not ( r = -0.14, NS). Table  2 shows the relationships between various non-invasive indices of cardiac function, and IrANP and catecholamines, respectively. Neither catecholamines nor IrANP (Fig. l b ) were related to left atrial dimension, but the levels of IrANP were significantly correlated with wall motion score (Fig. l c ) and to end-systolic wall stress. There was an inverse correlation between IrANP and ejection fraction (Fig. I d ) . Furthermore, there was a fair correlation between IrANP and apexcardiographic (rapid filling wave; r=0.46, P < O . O l ) as well as phonocardiographic (third heart sound; r = 0.49, P<O.OOl) indices of cardiac function. Noradrenaline and adrenaline were not related to any of these indices. IrANP, noradrenaline and adrenaline were not found to be related to left ventricular hypertrophy as measured by posterior wall thickness. Pronounced failure in the dyspnoea grade 4 group is illustrated by the increased 'heart rate (Table 3) , which was high in spite of investigation after prolonged supine rest, a procedure causing low heart rate in men with lower grade dyspnoea and in control subjects. Plasma IrANP was related to the use of diuretics ( Table 3) . IrANP was significantly ( P < 0.05) increased and plasma sodium was significantly ( P < 0.05) decreased in the most severe dyspnoea grade group, as compared with the control group. However, in the whole study group ( n = 87), generally no significant relationships were found between IrANP, noradrenaline or adrenaline, respectively, and the overall level of biochemical variables, such as plasma electrolytes, protein or creatinine.
The multivariate analysis of the clinical variables listed in Table 1 showed that angina pectoris, radiological signs of pulmonary congestion and electrocardiographic Q-waves were independently related to dyspnoea grade. When these three variables were accounted for, IrANP, but not noradrenaline or adrenaline, was still significantly related to dyspnoea grade ( Table 4 ). The three clinical variables angina pectoris, pulmonary congestion and Q-waves were brought together into a clinical score and yielded, if present, one point each. Fig. 2 shows the mean dyspnoea grade in groups of men as determined by clinical score and circulating IrANP. A high value of IrANP was found to be a specific but insensitive marker of impaired myocardial function as evidenced by an increased left atrium [36] , wall motion disturbances [34] or a low ejection fraction [35] (Table 5) .
DISCUSSION
In the present cross-sectional study, we found IrANP to be related, not only to cardiac dyspnoea, but also to 
Table 2. Indices of cardiac dysfunction and their relation to venous IrANP and catecholamines
Values are means k SEM. Abbreviations: 2D Echo, two-dimensional echocardiography; ESWS, end-systolic wall stress; LV, left ventricular; mean Vcf,, heart rate corrected mean velocity of circumferential fibre shortening; NS, not significant. various indices of impaired cardiac function, and particularly to those expressing severe heart failure. However, the correlations were weak or fair and scatters were wide. Previous investigations of plasma IrANP have been directed towards patient populations with definite, and often severe, cardiac dysfunction. These studies do not determine whether measurements of plasma IrANP would be of value in the evaluation of heart failure in the general population. The present study was therefore designed to evaluate, in a strictly epidemiological sample, the possible value of IrANP in population studies. To further clarify possible relationships we included only dyspnoeic subjects with any one indication of heart disease and excluded those with indications of obstructive pulmonary disease. Influence of age [22] on the level of IrANP was avoided by studying a homogeneous age group. Furthermore, a variety of clinical, echocardiographic and other non-invasive indices of heart function was applied.
After the first report by Tikkanen et al. [ll] of increased circulating concentrations of IrANP in patients with congestive heart failure, this finding has been confirmed by a number of studies [6, [12] [13] [14] [15] [16] [17] [18] [19] 24 ,25,28-331. In the rat, turnover rate and depleted stores of atrial natriuretic peptide relate to the severity of heart failure [28] . Since raised left atrial pressure or stretch is an important stimulus to ANP release [8, 9] , the level of IrANP may be anticipated to correlate with left atrial dimension. In spite of this, and confirming previous findings [40] , there was no such relation in the present study population. Also confirming recent findings [41] , we found no relation between immunoreactivity and exercise capacity. The relation between IrANP and breathlessness was not as consistent as recently reported [13, 19, 291 , probably due to fewer subjects with severe heart failure in the present study. However, when compared with the control group, plasma from the men in the most severe dyspnoea grade group displayed significantly higher concentrations of IrANP, probably secondary to raised atrial pressure and not due to a decreased tissue extraction. Degradation in the pulmonary circulation has little clinical significance in the measurement of endogenous ANP [8] , while a 30-50% extraction occurs during one passage of circulation through the kidney, liver, intestine and lower limbs [42] . However, a decreased renal clearance of ANP, which could explain increased immunoreactivity, was unlikely in our group of dyspnoeic patients, since renal function, as measured by plasma creatinine, was similar in all groups of men. Furthermore, IrANP was significantly related to dyspnoea grade as well as to pulmonary congestion and heart size as measured by chest X-ray. It should be noted that the immunoreactivity was most closely correlated to the rapid filling wave, the third heart sound and the pulmonary component of the second heart sound. These variables are abnormal mainly in severe heart failure with a raised left ventricular filling pressure and increased pulmonary artery pressure at rest [36] . In the present study population such abnormalities characterized the dyspnoea grade 4 group, but not lower dyspnoea grade groups. The latter groups had normal ejection fraction, and their dyspnoea was probably mainly caused by diastolic or regional abnormalities [34-361. Thus, an elevated level of IrANP was associated with severe dyspnoea in men with systolic dysfunction, and particularly with signs of raised pulmonary artery pressure and severe heart failure.
In the present investigation, sampling from the pulmonary artery or right ventricle [18, 24, 32, 431 might have increased correlations between IrANP concentrations and measures of cardiac function. Such an approach was, however, not considered ethically or practically reasonable in a population study. In this type of investigation, as well as for clinical purposes, arterial sampling (not applied in the present study) may prove to be a useful alternative [8, 
18,241.
In patients with heart disease, the level of IrANP in the pulmonary artery increased with exercise, in relation to a concomitant increase of the pulmonary artery wedge pressure [8, 25, 44] . It is therefore possible that peripheral IrANP sampled at the end of, or immediately after, exercise will reveal subjects with myocardial impairment better than IrANP sampled at rest 1451.
It is generally held that the activation of the sympathetic system, as well as of the renin-angiotensin and arginine vasopressin systems, is a compensatory response designed to improve the inadequate peripheral organ tissue flow, which is the basic disturbance in congestive heart failure [26]. Not only the sympathetic nervous system but also ANP seems to be involved in blood pressure regulation and tissue organ perfusion as well as in sodium homoeostasis [46] In the present study, concentrations of circulating noradrenaline also showed a correlation, albeit weaker than IrANP, with dyspnoea grade and with the radiological index of pulmonary congestion. Catecholamines were, in contrast t o IrANP, unrelated to various non-invasive measurements of cardiac dysfunction. Arterial noradrenaline has been found to lack correlation with invasive indices of cardiac function [49] , but a more than threefold increase has been found in congestive heart failure patients, and has been considered t o be a marker for a failing left ventricle [26, 49] as well as a biochemical indicator of a bad prognosis [27] . The fact that in the present study IrANP, but not noradrenaline, was related to cardiac dyspnoea when clinical variables were accounted for, points to the possibility that plasma IrANP may also be a prognostic index.
In conclusion, in a sample of 67-year-old men with cardiac dyspnoea drawn from the general population, peripheral resting venous IrANP is significantly increased in severe, but not in milder forms of heart failure. In spite of it being more closely related to cardiac function than are catecholamines, and despite contributing independently from clinical information t o the explanation of dyspnoea grade variance, circulating IrANP is an insensitive marker of cardiac dysfunction and correlates only weakly with radiological and echocardiographical measures of heart function. IrANP is, however, moderately correlated with measures expressing severe heart failure and raised pulmonary artery pressure. In large scale studies, therefore, the individuals with severe cardiac dysfunction are likely to be detected by analysis of peripherally sampled IrANP, although all subjects with impaired myocardial function will not be revealed.
Whether arterial and exercise related blood sampling will increase the clinical usefulness of analysis of IrANP, and whether this peptide is a n indicator of prognosis, remains to be elucidated.
